Clinical trial of acetylenic carbamate: 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NSC-112682).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000480:Alkynes / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006049:Gold Isotopes; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011859:Radiography; D011877:Radionuclide Imaging; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000480:Alkynes; D000970:Antineoplastic Agents; D002219:Carbamates; D003510:Cyclohexanes; D006049:Gold Isotopes